<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05109091</url>
  </required_header>
  <id_info>
    <org_study_id>ATH434-201</org_study_id>
    <nct_id>NCT05109091</nct_id>
  </id_info>
  <brief_title>Study of ATH434 in Participants With Multiple System Atrophy</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in Multiple System Atrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alterity Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alterity Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of ATH434 in participants with Multiple System&#xD;
      Atrophy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in iron content as measured by brain MRI</measure>
    <time_frame>Change from Baseline to Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Aggregating alpha-Synuclein Levels</measure>
    <time_frame>Change from Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neurofilament Light Chain Levels</measure>
    <time_frame>Change from Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Unified MSA Rating Scale (UMSARS) Score</measure>
    <time_frame>Change from Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SF-36 Score</measure>
    <time_frame>Change from Baseline to Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Multiple System Atrophy</condition>
  <arm_group>
    <arm_group_label>ATH434 Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ATH434 Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATH434 dose level 1</intervention_name>
    <description>ATH434 taken BID</description>
    <arm_group_label>ATH434 Arm 1</arm_group_label>
    <other_name>PBT434</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATH434 dose level 2</intervention_name>
    <description>ATH434 taken BID</description>
    <arm_group_label>ATH434 Arm 2</arm_group_label>
    <other_name>PBT434</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo taken BID</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant has clinical features of parkinsonism.&#xD;
&#xD;
          2. Participant has evidence of autonomic dysfunction.&#xD;
&#xD;
          3. Participant has at least one supportive clinical feature of MSA.&#xD;
&#xD;
          4. Participant is ambulatory.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participant has long duration of motor symptoms.&#xD;
&#xD;
          2. Participant has advanced disease.&#xD;
&#xD;
          3. Participant has structural brain abnormality on MRI.&#xD;
&#xD;
          4. Participant has any significant neurological disorder other than MSA.&#xD;
&#xD;
          5. Participant has an unstable medical or psychiatric illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 22, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple System Atrophy</keyword>
  <keyword>ATH434</keyword>
  <keyword>Neurodegenerative disease</keyword>
  <keyword>Shy-Drager Syndrome</keyword>
  <keyword>Movement disorders</keyword>
  <keyword>Autonomic dysfunction</keyword>
  <keyword>Synucleinopathies</keyword>
  <keyword>Atypical parkinsonism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple System Atrophy</mesh_term>
    <mesh_term>Shy-Drager Syndrome</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

